Peptide Cycles & Dosing Protocols

Why Cycles Exist in the First Place

The concept of a "cycle" in peptide research draws from decades of experience with hormonally active compounds, but it applies to peptides differently than it does to, say, anabolic steroids. For steroids, cycling is primarily about managing long-term damage to endogenous testosterone production and recovering HPTA function. For peptides, cycling is about something more nuanced: preserving receptor sensitivity, maintaining physiological feedback loops, and — in some cases — preventing the body from treating a continuously-administered signal as baseline and dismissing it.

Not every peptide requires cycling, and a lot of online advice about cycling applies blanket rules that do not hold up to specific compound pharmacology. GHK-Cu, a naturally-occurring tripeptide, is well-tolerated in continuous daily use and has no meaningful desensitization profile. BPC-157, in contrast, is almost always cycled because research use is injury-driven — when the injury heals, the reason to keep dosing disappears. CJC-1295 plus Ipamorelin, a GH secretagogue stack, benefits from periodic breaks because sustained pituitary stimulation can blunt response over multi-month horizons. The right cycle depends entirely on the peptide and the research goal.

Cycle Reference by Peptide Class

Titration Is the Most Important Dosing Skill

Every peptide protocol in this catalog should start at or below the lower end of the recommended dose range, not at the middle or the upper end. The reason is simple: individual response variation is significant, and most peptide side effects are dose-dependent. A researcher who starts BPC-157 at 250 mcg and finds it tolerable can always increase to 500 mcg next week. A researcher who starts at 500 mcg and experiences fatigue or GI upset cannot undo that first dose, and has to pause for several days to differentiate the peptide from other variables.

For compounds with meaningful side-effect profiles — anything in the GLP-1 class, anything in the melanocortin class — titration is not optional. Tirzepatide protocols, for example, universally begin at 2.5 mg weekly for four weeks before any increase is considered, and each subsequent increase is held for at least four weeks before the next. Trying to compress this schedule produces severe GI symptoms that could have been avoided entirely. Melanotan II benefits from the same discipline: 250 mcg initial dose, observe the response for 24 hours, escalate only if tolerated.

Pyramid Dosing: When It Helps and When It Doesn't

Some researchers use pyramid dosing — ramping the dose up to a peak in the middle of a cycle, then ramping back down before cessation — on the theory that this gently re-introduces endogenous activity and prevents post-cycle crashes. For peptides that stimulate production of downstream hormones (CJC-1295, Sermorelin), this approach has some theoretical merit: tapering off over the last two weeks of a cycle may help the pituitary gradually resume baseline function rather than experiencing an abrupt return to pre-cycle signaling.

For most other peptides, pyramid dosing is aesthetic rather than functional. BPC-157 works through local tissue signaling that resolves when exogenous input stops; there is no "pituitary recovery" to manage. GHK-Cu does not produce any rebound; neither does most of the cognitive peptide class. Spending mental effort on elaborate pyramid schedules when the underlying peptide does not require them is a form of protocol theater. Match the sophistication of your cycling to the complexity of the compound.

Stacking: Two Peptides Are Not Always Better

Peptide stacking is common, often useful, and occasionally counterproductive. The most thoroughly-studied stack in this space is CJC-1295 plus Ipamorelin — two GH secretagogues that work through different receptors (GHRH and ghrelin, respectively) and produce a larger combined GH pulse than either alone. This is a textbook example of pharmacologic synergy and is the default protocol for most GH research. BPC-157 combined with TB-500 is another well-studied pair, targeting different aspects of tissue repair and producing faster healing in preclinical injury models than either compound in isolation.

Other combinations are less clearly beneficial. Combining multiple metabolic peptides (e.g., Tirzepatide plus 5-Amino-1MQ) may produce additive side effects without additive efficacy. Combining too many cognitive peptides (Semax, Selank, and a nootropic stack simultaneously) obscures which compound is driving which subjective effect, making protocol iteration impossible. Rule of thumb: two peptides with different mechanisms that target the same research outcome — stack. Two peptides with overlapping mechanisms — rarely worth the complexity.

Tracking Is What Separates Research From Guessing

A peptide protocol run without measurement is just experimentation without data. The minimum viable tracking setup includes: a log of every dose with exact time and amount, subjective notes on sleep quality, energy, mood, and any side effects, weekly photos if aesthetic outcomes are part of the research goal, and periodic measurements (weight, waist, strength benchmarks) if performance is the goal. For longer or more complex protocols, quarterly bloodwork is genuinely valuable — IGF-1 levels for GH secretagogue research, fasting glucose and HbA1c for metabolic compounds, inflammatory markers for healing protocols. These are the measurements that let you distinguish a working protocol from a placebo effect, a bad batch from genuine non-response, and an acceptable side effect from a warning sign worth investigating.

Protocol-Ready Peptides

Healing & Recovery

BPC-157 10mg

Body Protection Compound 157 — one of the most studied healing peptides for tissue repair and gut health.

$59.99$53.99—Buy Now

Growth Hormone

CJC-1295 No DAC 10mg

GHRH analog — stimulates natural pulsatile growth hormone release. Pairs with Ipamorelin.

$79.99$71.99—Buy Now

Growth Hormone

Ipamorelin 10mg

Selective GH secretagogue with minimal side effects — the cleanest GHRP available.

$59.99$53.99—Buy Now

Metabolic

Tirzepatide 15mg

Dual GIP/GLP-1 receptor agonist — clinical trials show 20%+ average weight loss.

$149.99$134.99—Buy Now